A Computer-based Cognitive Stimulation in Mild Cognitive Impairment With White Matter Hyperintensities
Launched by LEILA DJABELKHIR · Jun 20, 2017
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
White matter hyperintensities (WMH) can appear in Mild Cognitive Impairment (MCI) and have been associated to executive, attention and processing speed deficits. Some findings indicate that the presence of WMH may contribute to Alzheimer's disease (AD) in addition to ß-amyloid, suggesting a greater vulnerability of MCI. One important challenge is to prevent or slowing down the progression of WMH. Few studies investigated the effects of computerized cognitive interventions in MCI with WMH, which deserve special attention. This study aim to investigate the effects of an intensive computer-bas...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Mild Cognitive Impairment
- • With and without with matter hyperintensities
- • MRI data available or accept to perform one
- • No engagement in other cognitive intervention program
- Exclusion Criteria:
- • Psychiatric and neurological disorders
- • History of alcohol or other substance consumption
- • Sensory and or motor deficit that could interfere with the use of computer tool
- • Refusal MRI.
About Leila Djabelkhir
Leila Djabelkhir is a dedicated clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical development and regulatory affairs, she leads initiatives that focus on innovative therapies across various therapeutic areas. Her approach emphasizes collaboration with healthcare professionals, adherence to ethical standards, and the integration of patient perspectives in the research process. Through her leadership, Leila Djabelkhir aims to facilitate the successful transition of promising treatments from the research phase to clinical practice, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anne-Sophie AR RIGAUD, Professor
Principal Investigator
Broca University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials